No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization

J Infect Dis. 2010 Apr 15;201(8):1192-200. doi: 10.1086/651378.

Abstract

Background: Mutants of the a determinant of hepatitis B surface antigen (HBsAg) can escape neutralization by vaccine-induced antibodies and prevail in an immunized population.

Methods: We evaluated the a mutants in a pediatric population surveyed in 2004 and compared these findings with the data of previous surveys.

Results: There were 38 children and 74 adolescents who were HBsAg positive, and serum hepatitis B virus (HBV) DNA was obtained and tested from 31 and 34 of them, respectively. The a mutants were found in 7 (22.6%) of 31 HBV DNA-positive children and in 7 (0.10%) of 7234 children, the entire population that was surveyed in 2004. After the beginning of universal immunization, the very low prevalence of mutants has remained unchanged for 20 years. More a mutants were found in immunized than in nonimmunized HBV DNA-positive children aged 1-4 years old (31% vs 4%, P = .016) but not in those children aged 5-12 years old. Approximately 68% of immunized, mutant-infected children had carrier mothers. More a mutants emerged in children immunized with plasma-derived vaccines than in those immunized with recombinant vaccines (14 of 5166 vs 3 of 4970, respectively; P = .04). HBV DNA levels were significantly lower in hepatitis B e antigen-positive sera containing the G145R mutant than were levels in sera containing wild-type virus. HBsAg-negative sera containing a mutants had very low HBV DNA levels.

Conclusions: Less infectivity of G145R, recombinant vaccine use, and mutant loss with older age seem to decrease the a mutant prevalence in an immunized population over time.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • DNA, Viral / blood
  • Epitopes / genetics
  • Epitopes / immunology
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B Surface Antigens / genetics
  • Hepatitis B Surface Antigens / immunology*
  • Hepatitis B Vaccines / genetics
  • Hepatitis B Vaccines / immunology*
  • Humans
  • Infant
  • Infant, Newborn
  • Mass Vaccination
  • Mutation
  • Polymerase Chain Reaction
  • Seroepidemiologic Studies
  • Taiwan / epidemiology
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology

Substances

  • DNA, Viral
  • Epitopes
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Vaccines, Synthetic